Medical Marijuana Inc. Shareholder Update

[Ms Chocolate]

There's stock for this company? How can we get some?

 

http://www.canchewbiotech.com/18-press/2012-press-releases/24-medical-marijuana-inc-acquires-50-stake-in-canchew-from-netherlands-based-sanammad-foundation

Medical Marijuana, Inc. Acquires 50% Stake in CanChew from Netherlands-based Sanammad Foundation

 

Deal Provides Cannabis and Hemp Innovators with Patents and Exclusive Rights to Produce First and Only Chewing Gum Delivery Mechanism for Cannabinoids

 

Denver, Colo. (June 5, 2012) —Medical Marijuana, Inc. (OTC PK: MJNA), a leading cannabis and hemp industry innovator, has acquired a 50 percent stake in CanChew, a cannabinoid (CBD)-based medicine delivery vehicle in the form of chewing gum. The product was previously owned entirely by Sanammad Foundation, a pharmaceutical development company headquartered in The Netherlands.

The acquisition includes ownership of the patents and intellectual property of the product giving Medical Marijuana, Inc. the worldwide exclusive rights to develop, manufacture, market and distribute both THC and non-THC hemp-derived cannabinoid infused chewing gum to medical marijuana consumers. The Food and Drug Administration (FDA) currently considers non-THC based hemp products to be “food based” and therefore legal without a medical marijuana license. Cannabinoids have had positive effects in clinical trials on neuralgic pain, Multiple Sclerosis and spinal cord injuries, nausea and vomiting from chemotherapy and radiation treatment as well as palliative treatment of various cancers and HIV/AIDS. Based on its therapeutic potential and federally legal status, Dixie and Medical Marijuana, Inc., estimate the medical cannabinoid market in the US to be well over $30 billion. The Company intends to begin production of the CBD-based gum, and in states where legally allowed a THC-infused product, within the next 90 days. Information regarding availability of the product will be posted to the Company’s website at http://www.medicalmarijuanainc.com.

 

 

 

 

 

http://www.medicalma...biotechnologies

 

Canchew Biotechnologies

 

Overview

 

CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets research and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms.

Product Development

 

CanChew Biotech has a patented technology which comprises the inclusion of regulatory acceptable active pharmaceutical ingredients [API] of the cannabinoid variety in a patented and proprietary chewing gum delivery formulation. CanChew® for medical purposes, specifically pain treatment associated with a variety of long term, chronic or degenerative diseases whereby cannabinoid therapy is finding increasing application in a global marketplace.

CanChew Advantage

 

The CanChew® formulation offers a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of the cannabis/cannabinoid(s) based medicine via the oral mucosal membranes.

CanChew's full oral-oropharyngeal mucous membrane delivery method is superior to other delivery methods.

Advantages of Oral Mucosal Drug Delivery system:

• Bypass of the gastrointestinal tract and hepatic portal system, increasing the bioavailability of orally administered drugs that otherwise undergo hepatic first-pass metabolism.
  
• Drug is protected from degradation due to pH and digestive enzymes of the middle gastrointestinal tract.
  
• Improved patient compliance due to the elimination of associated pain with injections.
  
• Sustained drug delivery.
  
• A relatively rapid onset of action can be achieved relative to the oral route.
  
• Oral mucosal systems exhibit a faster initiation and decline of delivery than do transdermal patches.
  
• The large contact surface of the oral cavity contributes to rapid and extensive drug absorption.
  

Edited July 13, 2012 by Ms Chocolate